- First independent launch underway following
TRYNGOLZATM approval -
- Second independent launch on track with
donidalorsen PDUFA August 21, 2025 -
- WAINUATM U.S. launch delivering accelerating
sequential growth -
- Ionis exceeds 2024 financial guidance and
provides full year 2025 guidance -
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) (the “Company”) today
reported financial results for the fourth quarter and full year
ended December 31, 2024.
“With the recent launch of our first independent medicine,
TRYNGOLZA for familial chylomicronemia syndrome, Ionis has begun a
new chapter as a fully integrated commercial-stage biotechnology
company,” said Brett P. Monia, Ph.D., chief executive officer,
Ionis. “Over the next three years, we expect three more independent
launches, including donidalorsen later this year for hereditary
angioedema and olezarsen for severe hypertriglyceridemia in 2026,
pending Phase 3 results in the second half of this year.
Additionally, our partners are on track to launch four
Ionis-discovered medicines over the same time period, including
several that address broad patient populations. Ionis continues to
advance our next wave of potentially transformational wholly owned
medicines, including ION582 for Angelman syndrome, which is on
track to start Phase 3 development in the first half of this year.
Our recent achievements, combined with our strong commercial
execution and advancing pipeline, position Ionis to deliver
increasing value for all our stakeholders.”
Fourth Quarter and Full Year 2024 Summary Financial
Results(1):
Three months ended December
31,
Year ended December 31,
2024
2023
2024
2023
(amounts in millions)
Total revenue
$
227
$
325
$
705
$
788
Operating expenses
$
337
$
331
$
1,180
$
1,141
Operating expenses on a non-GAAP basis
$
301
$
305
$
1,050
$
1,035
Loss from operations
$
(110
)
$
(6
)
$
(475
)
$
(353
)
Income (Loss) from operations on a
non-GAAP basis
$
(74
)
$
20
$
(345
)
$
(247
)
(1)
Reconciliation of GAAP to non-GAAP basis
contained later in this release.
Financial Highlights
- Revenue for the year ended December 31, 2024 substantially
exceeded guidance as Ionis continued to generate revenue from
diverse sources. Ionis added new sources of revenue in 2024 with
the launch of WAINUA and TRYNGOLZA in the U.S. in late January and
late December, respectively
- Operating expenses for the year ended December 31, 2024 were in
line with expectations with increased expenses from
commercialization efforts for WAINUA, TRYNGOLZA and
donidalorsen
- Cash, cash equivalents and short-term investments of $2.3
billion as of December 31, 2024 exceeded revised guidance and
enable continued investments to support ongoing and upcoming
planned launches and advancing wholly owned medicines in
development
Recent Highlights- Marketed Medicines
- TRYNGOLZATM (olezarsen) launch underway following approval on
December 19, 2024 in the U.S as first-ever treatment for adults
living with familial chylomicronemia syndrome (FCS) as an adjunct
to diet
- WAINUATM (eplontersen) (WAINZUA in EU) for the treatment of
adults with polyneuropathy of hereditary transthyretin-mediated
amyloidosis (ATTRv-PN) achieved multiple commercial and regulatory
milestones:
- Generated sales of $85 million resulting in royalty revenue of
$20 million in the year ended December 31, 2024. Substantial
sequential growth throughout 2024 as launch progressed, including
an 84% increase in product sales in the fourth quarter, compared to
the third quarter
- Launch underway in numerous countries, including the UK,
following approval by the Medicines and Healthcare products
Regulatory Agency (MHRA) with an accelerated National Institute for
Health and Care Excellence (NICE) recommendation
- Received positive Committee for Medicinal Products for Human
Use (CHMP) opinion from European Medicines Agency (EMA) for the
treatment of hereditary transthyretin-mediated amyloidosis in adult
patients with stage 1 or stage 2 polyneuropathy
- SPINRAZA® (nusinersen) for the treatment of spinal muscular
atrophy (SMA) generated global sales of $1.6 billion resulting in
royalty revenue of $216 million in year ended December 31, 2024.
Product sales increased 2% in the fourth quarter of 2024, compared
to the same period in 2023
- Higher dose nusinersen under regulatory review in U.S. (PDUFA
date of September 22, 2025) and EU
- QALSODY® (tofersen) for the treatment of SOD1-ALS generated
global sales of $32 million resulting in royalty revenue of $4
million in the year ended December 31, 2024. Product sales grew
sequentially throughout 2024
- Granted marketing approval in China and Japan
Recent Highlights- Late-Stage Pipeline
- Olezarsen on track for Phase 3 data in patients with severe
hypertriglyceridemia (sHTG) in H2:2025, positioning it to
potentially treat this second more prevalent patient population
with urgent unmet need
- Olezarsen and donidalorsen Canadian commercialization rights
licensed to Theratechnologies
- Donidalorsen on track for potential launch this year as the
first RNA-targeted prophylactic treatment for people with
hereditary angioedema (HAE):
- Under review in U.S. (PDUFA date of August 21, 2025) and
EU
- Presented positive Phase 2 open label extension (OLE) study
data demonstrating an overall sustained mean reduction in HAE
attack rates of 96% in patients treated up to three years with
every four weeks or every eight weeks dosing
- ION582 on track to initiate Phase 3 development in Angelman
syndrome (AS) in H1:2025
- Ulefnersen global commercialization rights licensed to Otsuka;
Phase 3 development ongoing for the treatment of patients with
FUS-ALS
Fourth Quarter, Full Year 2024 Financial Results and 2025
Financial Guidance
“In 2024, we exceeded our revenue guidance due to our continued
pipeline and technology successes, which drove a smaller than
anticipated operating loss. Importantly, we added two new sources
of commercial revenue with TRYNGOLZA product revenue from Ionis’
first independent launch and WAINUA royalties,” said Elizabeth L.
Hougen, chief financial officer, Ionis. “In 2025, we will continue
to invest in go-to-market activities for TRYNGOLZA for FCS and
scale our resources to support our next planned launches, including
donidalorsen for hereditary angioedema later this year. At the same
time, we are investing in our next wave of medicines, including
Phase 3 development and pre-commercialization activities for ION582
for Angelman syndrome. These important investments position Ionis
to deliver substantial and growing product revenue; and when
combined with increasing royalty revenue from anticipated partner
launches, provides us with a clear path to achieve sustained
positive cash flow.”
Revenue
Ionis’ revenue was comprised of the following:
Three months ended
Year ended
December 31,
December 31,
2024
2023
2024
2023
Revenue:
(amounts in millions)
Commercial revenue:
SPINRAZA royalties
$
64
$
62
$
216
$
240
WAINUA royalties
10
-
20
-
Other commercial revenue:
TEGSEDI and WAYLIVRA revenue, net
8
9
34
35
Other revenue
4
8
23
34
Total commercial revenue
86
79
293
309
Research and development revenue:
Amortization from upfront payments
27
76
132
125
Milestone payments
30
11
106
101
License fees
34
92
71
117
Other services
6
-
24
10
Collaborative agreement revenue
97
179
333
353
WAINUA joint development revenue
44
67
79
126
Total research and development revenue
141
246
412
479
Total revenue
$
227
$
325
$
705
$
788
Commercial revenue for the year ended December 31, 2024 included
new sources of commercial revenue with the launch of WAINUA in the
U.S. in late January 2024 and the launch of TRYNGOLZA in the U.S.
in late December 2024. SPINRAZA product sales in the U.S. increased
slightly in 2024 compared to 2023. SPINRAZA product sales outside
of the U.S. were impacted from an annual order from a single
country that did not recur in 2024.
R&D revenue decreased for the year ended December 31, 2024
compared to 2023 primarily due to the decrease in WAINUA joint
development revenue as development activities relating to ATTRv-PN
wound down with the launch of WAINUA.
Operating Expenses
Ionis’ operating expenses increased slightly for the year ended
December 31, 2024 compared to 2023. SG&A expenses increased
year over year primarily due to the launches of WAINUA and
TRYNGOLZA, and advancing launch preparation activities for
donidalorsen. R&D expenses were flat year over year.
Balance Sheet
As of December 31, 2024, Ionis’ cash, cash equivalents and
short-term investments were $2.3 billion, consistent with December
31, 2023. In September 2024, Ionis generated gross proceeds of $500
million from a public offering of its common stock. Ionis’ working
capital increased as of December 31, 2024, compared to December 31,
2023 primarily from the Company’s lower current liabilities as a
result of lower deferred contract revenue.
2025 Financial Guidance
The Company’s 2025 financial guidance reflects its evolution to
a fully integrated commercial-stage biotechnology company
independently launching its first medicine, TRYNGOLZA, and
advancing commercialization efforts for multiple additional
upcoming planned launches. As a result, the Company expects to earn
substantial revenue from numerous diverse sources, with a shift
toward increasing commercial revenue. Additionally, the Company
expects a modest increase in its non-GAAP operating expenses in
line with its plan to invest in the Company’s independent launches
and advance its wholly owned pipeline of innovative medicines. The
Company expects that these investments will enable Ionis to deliver
accelerating value.
Full Year 2025 Guidance
Revenue
>$600 million
Operating loss on a non-GAAP basis
<$495 million
Cash, cash equivalents and short-term
investments
~$1.7 billion
Webcast
Management will host a conference call and webcast to discuss
Ionis’ fourth quarter and full year 2024 results at 11:30 a.m.
Eastern time on Wednesday, February 19, 2025. Interested parties
may access the webcast here. A webcast replay will be available for
a limited time at the same address. To access the Company’s fourth
quarter and full year 2024 earnings slides click here.
For more information about SPINRAZA and QALSODY, visit
https://www.spinraza.com/ and https://www.qalsody.com/,
respectively. QALSODY is approved under accelerated approval based
on reduction in plasma neurofilament light chain (NfL) observed in
patients treated with QALSODY. Continued approval may be contingent
upon verification of clinical benefit in confirmatory trial(s).
INDICATION for TRYNGOLZA™ (olezarsen)
TRYNGOLZA™ (olezarsen) was approved by the U.S. Food and Drug
Administration as an adjunct to diet to reduce triglycerides in
adults with familial chylomicronemia syndrome (FCS).
IMPORTANT SAFETY INFORMATION
CONTRAINDICATIONS
TRYNGOLZA is contraindicated in patients with a history of
serious hypersensitivity to TRYNGOLZA or any of the excipients in
TRYNGOLZA. Hypersensitivity reactions requiring medical treatment
have occurred.
WARNINGS AND PRECAUTIONS
Hypersensitivity Reactions
Hypersensitivity reactions (including symptoms of bronchospasm,
diffuse erythema, facial swelling, urticaria, chills and myalgias)
have been reported in patients treated with TRYNGOLZA. Advise
patients on the signs and symptoms of hypersensitivity reactions
and instruct patients to promptly seek medical attention and
discontinue use of TRYNGOLZA if hypersensitivity reactions
occur.
ADVERSE REACTIONS
The most common adverse reactions (incidence >5% of
TRYNGOLZA-treated patients and >3% higher frequency than
placebo) were injection site reactions, decreased platelet count
and arthralgia.
Please see full Prescribing Information for TRYNGOLZA.
INDICATION for WAINUA™ (eplontersen)
WAINUA injection, for subcutaneous use, 45 mg is indicated for
the treatment of the polyneuropathy of hereditary
transthyretin-mediated amyloidosis in adults.
IMPORTANT SAFETY INFORMATION for WAINUA™
(eplontersen)
WARNINGS AND PRECAUTIONS
Reduced Serum Vitamin A Levels and Recommended
Supplementation WAINUA leads to a decrease in serum vitamin A
levels. Supplement with recommended daily allowance of vitamin A.
Refer patient to an ophthalmologist if ocular symptoms suggestive
of vitamin A deficiency occur.
ADVERSE REACTIONS
Most common adverse reactions (≥9% in WAINUA-treated patients)
were vitamin A decreased (15%) and vomiting (9%).
Please see link to U.S. Full Prescribing Information for
WAINUA.
About Ionis Pharmaceuticals, Inc.
For three decades, Ionis has invented medicines that bring
better futures to people with serious diseases. Ionis currently has
six marketed medicines and a leading pipeline in neurology,
cardiology and select areas of high patient need. As the pioneer in
RNA-targeted medicines, Ionis continues to drive innovation in RNA
therapies in addition to advancing new approaches in gene editing.
A deep understanding of disease biology and industry-leading
technology propels our work, coupled with a passion and urgency to
deliver life-changing advances for patients. To learn more about
Ionis, visit Ionis.com and follow us on X (Twitter), LinkedIn and
Instagram.
Ionis’ Forward-looking Statement
This press release includes forward-looking statements regarding
Ionis’ business, financial guidance and the therapeutic and
commercial potential of our commercial medicines, additional
medicines in development and technologies. Any statement describing
Ionis’ goals, expectations, financial or other projections,
intentions or beliefs is a forward-looking statement and should be
considered an at-risk statement. Such statements are subject to
certain risks and uncertainties including those inherent in the
process of discovering, developing and commercializing medicines
that are safe and effective for use as human therapeutics, and in
the endeavor of building a business around such medicines. Ionis’
forward-looking statements also involve assumptions that, if they
never materialize or prove correct, could cause its results to
differ materially from those expressed or implied by such
forward-looking statements. Although Ionis’ forward-looking
statements reflect the good faith judgment of its management, these
statements are based only on facts and factors currently known by
Ionis. Except as required by law, we undertake no obligation to
update any forward-looking statements for any reason. As a result,
you are cautioned not to rely on these forward-looking statements.
These and other risks concerning Ionis' programs are described in
additional detail in Ionis' annual report on Form 10-K for the year
ended December 31, 2023, and most recent Form 10-Q, which are on
file with the Securities and Exchange Commission. Copies of these
and other documents are available from the Company.
In this press release, unless the context requires otherwise,
“Ionis,” “Company,” “we,” “our” and “us” all refer to Ionis
Pharmaceuticals and its subsidiaries.
Ionis Pharmaceuticals® is a registered trademark of Ionis
Pharmaceuticals, Inc. TRYNGOLZATM is a trademark of Ionis
Pharmaceuticals, Inc. Akcea Therapeutics® is a registered trademark
of Akcea Therapeutics, Inc. TEGSEDI® is a registered trademark of
Akcea Therapeutics, Inc. WAYLIVRA® is a registered trademark of
Akcea Therapeutics, Inc. SPINRAZA® and QALSODY® are registered
trademarks of Biogen. WAINUATM is a registered trademark of the
AstraZeneca group of companies.
IONIS PHARMACEUTICALS, INC.
SELECTED FINANCIAL INFORMATION
Condensed Consolidated
Statements of Operations (In Millions, Except Per Share
Data)
Three months ended
Year ended
December 31,
December 31,
2024
2023
2024
2023
(unaudited)
Revenue:
Commercial revenue:
SPINRAZA royalties
$
64
$
62
$
216
$
240
WAINUA royalties
10
-
20
-
Other commercial revenue
12
17
57
69
Total commercial revenue
86
79
293
309
Research and development revenue:
Collaborative agreement revenue
97
179
333
353
WAINUA joint development revenue
44
67
79
126
Total research and development revenue
141
246
412
479
Total revenue
227
325
705
788
Expenses:
Cost of sales
4
3
11
9
Research, development and patent
245
257
902
900
Selling, general and administrative
88
71
267
232
Total operating expenses
337
331
1,180
1,141
Loss from operations
(110
)
(6
)
(475
)
(353
)
Other income (expense):
Interest expense related to the sale of
future royalties
(19
)
(18
)
(73
)
(69
)
Other income, net
22
21
88
88
Loss before income tax benefit
(expense)
(107
)
(3
)
(460
)
(334
)
Income tax benefit (expense)
3
(6
)
6
(32
)
Net loss
$
(104
)
$
(9
)
$
(454
)
$
(366
)
Basic and diluted net loss per share
$
(0.66
)
$
(0.06
)
$
(3.04
)
$
(2.56
)
Shares used in computing basic and diluted
net loss per share
158
144
150
143
IONIS PHARMACEUTICALS, INC.
Reconciliation of GAAP to Non-GAAP Basis:
Condensed Consolidated
Operating Expenses, Loss From Operations, and Net Loss (In
Millions)
Three months ended December
31,
Year ended December 31,
2024
2023
2024
2023
(unaudited)
As reported research, development and
patent expenses according to GAAP
$
245
$
257
$
902
$
900
Excluding compensation expense related to
equity awards
(25
)
(20
)
(92
)
(78
)
Non-GAAP research, development and
patent expenses
$
220
$
237
$
810
$
822
As reported selling, general and
administrative expenses according to GAAP
$
88
$
71
$
267
$
232
Excluding compensation expense related to
equity awards
(11
)
(6
)
(37
)
(27
)
Non-GAAP selling, general and
administrative expenses
$
77
$
65
$
230
$
205
As reported operating expenses
according to GAAP
$
337
$
331
$
1,180
$
1,141
Excluding compensation expense related to
equity awards
(36
)
(26
)
(130
)
(106
)
Non-GAAP operating expenses
$
301
$
305
$
1,050
$
1,035
As reported loss from operations
according to GAAP
$
(110
)
$
(6
)
$
(475
)
$
(353
)
Excluding compensation expense related to
equity awards
(36
)
(26
)
(130
)
(106
)
Non-GAAP loss from operations
$
(74
)
$
20
$
(345
)
$
(247
)
As reported net loss according to
GAAP
$
(104
)
$
(9
)
$
(454
)
$
(366
)
Excluding compensation expense related to
equity awards and related tax effects
(36
)
(26
)
(130
)
(106
)
Non-GAAP net loss
$
(68
)
$
17
$
(324
)
$
(260
)
Reconciliation of GAAP to Non-GAAP
Basis
As illustrated in the Selected Financial Information in this
press release, non-GAAP operating expenses, non-GAAP loss from
operations, and non-GAAP net loss were adjusted from GAAP to
exclude compensation expense related to equity awards and the
related tax effects. Compensation expense related to equity awards
are non-cash. These measures are provided as supplementary
information and are not a substitute for financial measures
calculated in accordance with GAAP. Ionis reports these non-GAAP
results to better enable financial statement users to assess and
compare its historical performance and project its future operating
results and cash flows. Further, the presentation of Ionis’
non-GAAP results is consistent with how Ionis’ management
internally evaluates the performance of its operations.
IONIS PHARMACEUTICALS,
INC. Condensed Consolidated Balance Sheets (In
Millions)
December 31,
December 31,
2024
2023
(unaudited)
Assets:
Cash, cash equivalents and short-term
investments
$
2,298
$
2,331
Contracts receivable
92
98
Other current assets
230
213
Property, plant and equipment, net
94
71
Right-of-use assets
162
172
Other assets
127
105
Total assets
$
3,003
$
2,990
Liabilities and stockholders’ equity:
Current portion of deferred contract
revenue
$
79
$
151
0.125% convertible senior notes, net –
short-term
-
44
Other current liabilities
229
253
1.75% convertible senior notes, net
565
562
0% convertible senior notes, net
629
625
Liability related to sale of future
royalties, net
542
514
Long-term lease liabilities
162
171
Long-term obligations, less current
portion
52
42
Long-term deferred contract revenue
157
241
Total stockholders’ equity
588
387
Total liabilities and stockholders’
equity
$
3,003
$
2,990
Key 2025 and 2026 Value Driving Events(1)
New Product Launches
Program
Indication
2025
2026
Donidalorsen (U.S.)
HAE
•
TRYNGOLZA (U.S.)
FCS
Achieved
WAINZUA (EU)
ATTRv-PN
•
Olezarsen (U.S.)
sHTG
•
Zilganersen (U.S.)
Alexander disease
•
Regulatory Actions
Program
Indication
Regulatory Action
2025
2026
Donidalorsen
HAE
U.S. approval decision
•
EU approval decision
•
TRYNGOLZA
FCS
EU approval decision
•
Olezarsen
sHTG
U.S. submission
•
U.S. approval decision
•
Zilganersen
Alexander disease
U.S. submission
•
U.S. approval decision
•
Nusinersen
(higher dose)
SMA
U.S. and EU submissions
Achieved
U.S. approval decision
•
WAINZUA
ATTRv-PN
EU approval decision
•
Pelacarsen
Lp(a)- CVD
U.S. submission
•
Bepirovirsen
HBV
Regulatory submission(s)
•
Regulatory decision(s)
•
Key Phase 3 Clinical
Events
Program
Indication
Event
2025
2026
Olezarsen
sHTG
CORE, CORE2 and Essence data
•
Zilganersen
Alexander disease
Phase 3 data
•
ION582
Angelman syndrome
Phase 3 study start
•
Phase 3 enrollment completion
•
Pelacarsen
Lp(a)-CVD
HORIZON data
•
Bepirovirsen
HBV
B-Well data
•
Eplontersen
ATTR-CM
CARDIO-TTRansform data
•
Sefaxersen
IgAN
IMAGINATION data
•
Ulefnersen
FUS-ALS
Phase 3 data
•
(1)
Timing expectations based on current
assumptions and subject to change.
•
Indicates that the milestone is anticipated in the respective year
View source
version on businesswire.com: https://www.businesswire.com/news/home/20250219347982/en/
Ionis Investor Contact: D. Wade Walke, Ph.D. IR@ionis.com
760-603-2331
Ionis Media Contact: Hayley Soffer media@ionis.com
760-603-4679
Ionis Pharmaceuticals (NASDAQ:IONS)
Historical Stock Chart
From Feb 2025 to Mar 2025
Ionis Pharmaceuticals (NASDAQ:IONS)
Historical Stock Chart
From Mar 2024 to Mar 2025
